Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.
$XRAY
Medical/Dental Instruments
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/19/2026 | $17.00 | Neutral → Buy | BofA Securities |
| 12/9/2025 | $12.00 | Underweight | Barclays |
| 11/7/2025 | Outperform → Mkt Perform | William Blair | |
| 4/15/2025 | $14.00 | Overweight → Equal-Weight | Morgan Stanley |
| 3/13/2025 | Buy → Hold | Needham | |
| 2/14/2025 | $20.00 | Equal Weight | Wells Fargo |
| 1/23/2025 | $30.00 → $20.00 | Buy → Hold | Jefferies |
| 1/7/2025 | $20.00 | Outperform → In-line | Evercore ISI |
CHARLOTTE, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled to present on Tuesday, March 10, 2026, at 10:00 a.m. EST. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation
News Summary Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of taxQ4 2025 adjusted EPS of $0.27FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50(1)Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistryInitiated new capital allocation strategy by eliminating the dividend
CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the "Board"), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experience helping companies develop strategies to drive profitable growth and long-term value creation. Mr. Forbes is widely recognized for advising healthcare companies on complex strategic transactions and capital markets engagements. He most recently served as Vice Chairman of Investment Banking at Morgan Stanley, and he previously held senior execu
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
BofA Securities upgraded Dentsply Sirona from Neutral to Buy and set a new price target of $17.00
Barclays initiated coverage of Dentsply Sirona with a rating of Underweight and set a new price target of $12.00
William Blair downgraded Dentsply Sirona from Outperform to Mkt Perform
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
10-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the "Board"), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experience helping companies develop strategies to drive profitable growth and long-term value creation. Mr. Forbes is widely recognized for advising healthcare companies on complex strategic transactions and capital markets engagements. He most recently served as Vice Chairman of Investment Banking at Morgan Stanley, and he previously held senior execu
CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership
CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona's continued focus on strengthening commercial execution, deepening customer relationships and accelerating growth across the Americas. Mr. Bezjak is a seasoned commercial executive with more than 20 years of experience leading large-scale, multi-billion-dollar organizations in the medical device
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
News Summary Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of taxQ4 2025 adjusted EPS of $0.27FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50(1)Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistryInitiated new capital allocation strategy by eliminating the dividend
CHARLOTTE, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, February 26, 2026, at 4:30 p.m. EST to review its fourth quarter and full year 2025 financial results. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at http
CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026, to holders of record as of December 26, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including den